Highlights
1 patentProfile claimed by owner
About
Nano-Tech Cannabinoid products
Elixie is a clinical-stage biotech company enhancing cannabinoids for symptomatic relief of neurological disorders based on NANOLIX, a patented clinically proven Self-nano emulsifying drug delivery system (SNEDDS).
By encapsulating validated APIs in in-human-proven NANOLIX and targeting orphan diseases, Elixie will register pharmaceuticals in a relatively short route to market and with minimal risks.
Identity
| Name | Elixie |
|---|---|
| Slug | elixie-1 |
| Former names | Aset Dev Ltd |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4NGg3rUIDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Caesarea |
| HQ address | Tarshish Industrial Park St 5, Caesarea, Israel |
Web & social
| Website | https://www.elixie.com |
|---|---|
| https://www.linkedin.com/company/64527214 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyMedical CannabisDrug Delivery
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business models
B2B2CB2B
Tags
chronic-painnanotechnologymultiple-sclerosisdrug-deliverycannabispharma-companiesmedical-technologiespharmaceuticalsepilepsychronic-diseasemedical-cannabis
Funding
| Total raised | $2.0M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}